Baxter International Inc. (NYSE:BAX) today announced that it has entered
into an exclusive global agreement with Chatham Therapeutics, LLC, an
affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the
development and commercialization of potential treatments for hemophilia
B utilizing Chatham's gene therapy technology.
The collaboration will allow Baxter to investigate Chatham's Biological
Nano ParticlesTM (BNP), an advanced recombinant
adeno-associated virus-(rAAV) based gene therapy technology that has
shown potential therapeutic benefit in early clinical studies. A small
independent study involving six patients using Chatham technology
components was the topic of a 2011 article in The New England Journal
of Medicine. This agreement will involve the next
generation of this gene therapy technology, which Baxter and Chatham
will investigate through U.S.-based hemophilia B clinical trials. Baxter
has obtained global rights for the marketing and commercialization of
the new treatment.
''This collaboration demonstrates Baxter's ongoing commitment to
scientific innovation in advancing treatment options for patients living
with hemophilia. This initiative complements Baxter's extensive
hemophilia portfolio and helps to address unmet needs of hemophilia
patients,'' said Ludwig Hantson, Ph.D., president of Baxter's BioScience
Baxter made a $25 million upfront cash payment for the development and
advancement of the program through early clinical trials, and will
record this amount as a special pre-tax in-process research and
development charge in the second quarter of 2012. Baxter may make
additional payments over the next several years based on certain
development and commercial milestones.
''This agreement initiates a clinical development collaboration
dedicated to advancing a potential long-term treatment paradigm for
hemophilia patients. We look forward to working with Baxter and view
this transaction as the optimal path toward providing a sustainable
therapeutic to a worldwide patient population,'' said Jade Samulski,
Vice President at AskBio and Co-Founder of Chatham Therapeutics.
Source: Baxter International Inc.